151
|
Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB. Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 2006; 245:127-36. [PMID: 16626752 DOI: 10.1016/j.jns.2005.08.021] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2005] [Revised: 07/08/2005] [Accepted: 08/10/2005] [Indexed: 11/30/2022]
Abstract
Acetylcholinesterase inhibitors are used to treat dementia associated with Alzheimer's disease, but their cognitive benefits may extend to additional disorders such as multiple sclerosis (MS). A single-center double-blind placebo-controlled randomized clinical trial evaluated the effectiveness of donepezil in a sample of 69 MS persons selected for initial memory difficulties. Subjects received neuropsychological assessment at baseline and after 24 weeks of treatment. The primary outcome was change in total recall on the Selective Reminding Test, a measure of verbal learning and memory. Secondary outcomes included other neuropsychological tests from the Brief Repeatable Battery, patient-reported change in memory, and physician-reported impression of cognitive change. Donepezil improved memory performance on the SRT compared to placebo. This benefit remained significant after controlling for various covariates including Expanded Disability Status Scale (EDSS), MS subtype, interferon beta use, treatment group beliefs, gender, baseline selected reminding test (SRT) score, and reading ability. Subjects on donepezil were more likely to report memory improvement (65.7%) than those on placebo (32.4%). The clinician also reported cognitive improvement in more donepezil (54.3%) than placebo (29.4%) subjects. No serious adverse events related to study medication occurred. However, more donepezil (34.3%) than placebo (8.8%) subjects reported unusual/abnormal dreams. Donepezil improved learning and memory in MS patients with initial cognitive difficulties in a single-center clinical trial. Replication of results in a larger multi-center investigation is warranted in order to more definitively assess the efficacy of this intervention.
Collapse
|
152
|
Porcel J, Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J Neurol Sci 2006; 245:177-81. [PMID: 16674980 DOI: 10.1016/j.jns.2005.07.021] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2005] [Revised: 06/27/2005] [Accepted: 07/08/2005] [Indexed: 11/29/2022]
Abstract
Neuropsychological impairment is a common manifestation in multiple sclerosis (MS) and is found in 40-60% of patients. The pattern of cognitive impairment in MS is characterized by difficulties in recent memory, sustained attention, executive functions and information processing speed. These cognitive deficits have a significant impact on the patients' daily activities. However, there is no specific treatment available at present for cognitive disorders in MS patients. Treatment with acetylcholinesterase inhibitors (AChEI) has shown a positive effect on cognitive functions of patients with Alzheimer's disease and other conditions such as Lewy Body dementia, subcortical vascular dementia and Parkinson's disease. In this paper we review the results from studies and clinical trials aiming to demonstrate that AChEI could be a potential treatment for cognitive disorders in MS patients. Finally, we discuss future issues to take into consideration for AChEI treatments in the context of MS.
Collapse
Affiliation(s)
- J Porcel
- 2a Planta EUI, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Ps. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
| | | |
Collapse
|
153
|
Sartori E, Edan G. Assessment of cognitive dysfunction in multiple sclerosis. J Neurol Sci 2006; 245:169-75. [PMID: 16678209 DOI: 10.1016/j.jns.2005.07.016] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2005] [Revised: 07/07/2005] [Accepted: 07/12/2005] [Indexed: 11/27/2022]
Abstract
Cognitive deficit can be an early feature in the course of multiple sclerosis, may occur clinically isolated, impacts on social activities and could reflect disease progression that is independent of physical disability with potential therapeutical consequences. Neuropsychological tests should be independent of motor coordination or visuo-spatial ability, but sensitive to subtle cognitive changes, exploring attention speed and working memory They could be included in brief batteries with good normative data and alternative forms for future therapeutic trials. We recommend for a brief battery of neuropsychological tests the inclusion of PASAT and two memory tests: the learning stage of CVLT and backward Digit Span with a total time duration of 30 min. A complementary tool could be a cognitive questionnaire for informant. After a relapse, cognitive assessment should be performed at least 8 weeks afterwards. If the patient presents with psychiatric symptoms, a specific assessment should be proposed before starting a complete cognitive assessment. Finally, we propose some red flags warranting neuropsychological screening: patients with a mild physical disability, but unable to maintain their professional activities, pathological laughing-crying, increased age and low educational level.
Collapse
Affiliation(s)
- Eric Sartori
- Department of Neurology Rue Henri Le Guillou, CHU Pontchaillou, Rennes, France
| | | |
Collapse
|
154
|
Sartori E, Belliard S, Chevrier C, Trebon P, Chaperon J, Edan G. De la psychométrie au handicap neuropsychologique dans la sclérose en plaques. Proposition d’une batterie de dépistage en langue française et facteurs de risque cognitifs. Rev Neurol (Paris) 2006; 162:603-15. [PMID: 16710126 DOI: 10.1016/s0035-3787(06)75054-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Cognitive deficit in multiple sclerosis (MS) is a frequent early feature in the disease course, which conditions patients' overall disability. The goals of this study were to validate a reproducible brief screening battery written in French and to examine cognitive risk profiles in patients with a mild physical disability. METHODS Cognitive performances of 40 patients with EDSS <4.5 were compared with those of a control group. The study was completed with an analysis of socio-demographic, clinical and psychological variables (questionnaires). RESULTS Three tests were discriminative with satisfactory predictive values (positive: 88 percent; negative: 96 percent) and a time duration <30 minutes: PASAT (hard condition), backward digit span, learning stage of California Verbal Learning Test. Four variables were associated with cognitive deficit: educational level <11 years, age >40 years, pathological laughing-crying, unemployment. CONCLUSIONS Our brief battery is an easy and reproducible tool. Completed with warning signs indicating the need for neuropsychological screening, this tool provides the practitioner with a global means of assessing disease activity and potentially therapeutic efficacy.
Collapse
Affiliation(s)
- E Sartori
- Service de Neurologie, Centre Hospitalier de Bretagne Sud, Lorient.
| | | | | | | | | | | |
Collapse
|
155
|
Amato MP, Portaccio E, Zipoli V. Are there protective treatments for cognitive decline in MS? J Neurol Sci 2006; 245:183-6. [PMID: 16643949 DOI: 10.1016/j.jns.2005.07.017] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2005] [Revised: 07/06/2005] [Accepted: 07/12/2005] [Indexed: 11/30/2022]
Abstract
Despite its frequency and high functional impact, very little is known about effective strategies for managing cognitive impairment in multiple sclerosis (MS). Disease-modifying drugs, such as beta-interferons and glatiramer acetate, may prevent or reduce the progression of cognitive dysfunction by containing the development of new cerebral lesions. To date, clinical trials have provided inconsistent results, with neuropsychological effects documented only in one trial. Moreover, pilot studies have tested symptomatic therapies for fatigue, a frequent symptom in MS, which may share a common physiopathological substrate with cognitive dysfunction. Small trials with amantadine, pemoline, 4-aminopyridine and 3-4 aminopyridine have provided mainly negative results. Acetylcholinesterase inhibitors (AChEI) used to treat Alzheimer's disease (AD)-such as donepezil, rivastigmine, and galantamine-have recently been tested in other cognitive disorders, including MS. The majority of pilot trials with AchEI in MS have provided promising results, and the donepezil study recently published by Krupp et al. represents a major development in this field. As for non-pharmacological interventions based on cognitive rehabilitation, few studies have used an experimental approach and, in general, results have been disappointingly negative. Further research is clearly needed in this area.
Collapse
Affiliation(s)
- Maria Pia Amato
- Department of Neurology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy.
| | | | | |
Collapse
|
156
|
Benedict RHB, Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 2006; 245:67-72. [PMID: 16626751 DOI: 10.1016/j.jns.2005.05.020] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2005] [Revised: 05/25/2005] [Accepted: 05/25/2005] [Indexed: 11/17/2022]
Abstract
Multiple Sclerosis (MS) is associated with MRI signal alteration and neuropsychological (NP) dysfunction. Screening tools have been developed to identify patients at high risk for these neurological complications of MS. One such measure, the Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ), has well-established reliability and predictive validity. In this article, we report on the accumulated findings derived from 162 consecutive research participants and MS clinic attendees. Our data show significant correlation between both patient- and informant-report MSNQ and NP impairment. As shown previously, larger, and more significant correlations are found between informant-report MSNQs than with patient-report MSNQs. In addition, we find that the MSNQ predicts follow-up NP testing 51 weeks after baseline with a similar degree of association. Finally, the MSNQ is correlated with MRI measures of whole-brain lesion burden and atrophy, secondary progressive course, and vocational disability. We conclude that the MSNQ is reliable and valid for detecting neuropsychological and neuropsychiatric complications of MS.
Collapse
Affiliation(s)
- Ralph H B Benedict
- Department of Neurology, School of Medicine, State University of New York, SUNY at Buffalo, Buffalo General Hospital, Neurology, Suite D-6, 100 High Street, 14203, USA.
| | | |
Collapse
|
157
|
Zarei M. Clinical characteristics of cortical multiple sclerosis. J Neurol Sci 2006; 245:53-8. [PMID: 16626743 DOI: 10.1016/j.jns.2005.08.025] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2005] [Revised: 08/12/2005] [Accepted: 08/18/2005] [Indexed: 11/15/2022]
Abstract
There are several articles in this special issue in which authors eloquently describe neurobehavioural and cognitive complications of multiple sclerosis with relevant neuropsychological assessments and neuroimaging findings. However behavioural and cognitive presentation of multiple sclerosis remains poorly understood. Two years ago, we reported a series of patients with multiple sclerosis who presented with neurobehavioural symptoms and had neuropsychological deficits consistent with cortical dysfunction. Based on previous case reports, pathological studies of cerebral cortex in multiple sclerosis and advanced neuroimaging studies we suggested that neurobehavioural presentation of multiple sclerosis represents a new variant called "cortical multiple sclerosis". The condition is characterised by predominant or exclusive cortical pathology presenting with neurobehavioural symptoms, such as depression, amnesia or distinct cortical syndromes. Since the publication of our report, there has been further neuroimaging and neuropathological findings that further supported the above concept. In addition, observation of more patients with this condition helped us to formulate a logical approach in the detection of these patients. This article focuses on their clinical characteristics.
Collapse
Affiliation(s)
- Mojtaba Zarei
- Functional Magnetic Resonance Imaging of the Brain, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
| |
Collapse
|
158
|
Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Subcortical vascular cognitive impairment: similarities and differences with multiple sclerosis. J Neurol Sci 2006; 245:3-7. [PMID: 16626755 DOI: 10.1016/j.jns.2005.06.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2005] [Revised: 06/06/2005] [Accepted: 06/28/2005] [Indexed: 11/22/2022]
Abstract
Subcortical vascular cognitive impairment is caused by lacunes and widespread ischemic white matter damage which closely resembles white matter abnormalities seen in multiple sclerosis. Recent evidence suggests that the progression rate of ischemic white matter lesions on MRI is very similar to that observed in multiple sclerosis. Consequently, it has been proposed to use MRI for monitoring disease activity not only in multiple sclerosis but also in vascular dementia trials. There is first evidence from magnetization transfer imaging studies that other than in MS normal appearing white matter is not affected in cerebral small vessel disease. This contrasts the hypothesis that ischemic white matter damage extends far beyond changes visible on conventional MR. The cognitive consequences of both diseases are strikingly similar which is at least partly caused by damage to frontal-subcortical circuits. Involvement of these common functional anatomical structures and their modulatory transmitter systems has now led to common interventional approaches such as the use of cholinesterase inhibitors.
Collapse
Affiliation(s)
- Reinhold Schmidt
- Department of Neurology, Medical University Graz, Auenbruggerplatz 22, A-8036 Graz, Austria.
| | | | | | | | | |
Collapse
|
159
|
Nocentini U, Pasqualetti P, Bonavita S, Buccafusca M, De Caro MF, Farina D, Girlanda P, Le Pira F, Lugaresi A, Quattrone A, Reggio A, Salemi G, Savettieri G, Tedeschi G, Trojano M, Valentino P, Caltagirone C. Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12:77-87. [PMID: 16459723 DOI: 10.1191/135248506ms1227oa] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However, in the literature there are inconsistent reports on the prevalence of cognitive dysfunction, and separate data for the relapsing-remitting (RR) type of the disease are not always presented. In this study, we submitted 461 RRMS patients to a battery of neuropsychological tests to investigate their impairment in various cognitive domains. As a consequence of the exclusion criteria, the sample is not fully representative of the entire population of RRMS patients. In this selected sample, when only the eight scores of a core battery (Mental Deterioration Battery) were considered (with respective cutoffs), it emerged that 31% of the patients were affected by some degree of cognitive deficit. In particular, 15% had mild, 11.2% moderate and 4.8% had severe impairment. Information processing speed was the most frequently impaired area, followed by memory. When two other tests (SDMT and MCST) were added and cognitive domains were considered, it emerged that 39.3% of the patients were impaired in two or more domains. When four subgroups were obtained by means of cluster analysis and then compared, it emerged that information processing speed and memory deficits differentiated the still cognitively unimpaired from the mildly impaired MS patients. Significant associations were found between cognitive and clinical characteristics. However, due to the large sample size, clinically irrelevant relationships may also have emerged. Even with the limitations imposed by the sample selection and the possible underestimation of the prevalence and severity of cognitive dysfunction, these results seem to provide further evidence that information processing speed deficit may be an early and important marker of cognitive impairment in MS patients.
Collapse
Affiliation(s)
- U Nocentini
- Department of Neurology, University of Rome 'Tor Vergata' and IRCCS 'S. Lucia' Foundation, Rome, 00179 Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
160
|
Korsukewitz C, Breitenstein C, Schomacher M, Knecht S. Pharmakologische Zusatzbehandlung in der Aphasietherapie. DER NERVENARZT 2006; 77:403-15. [PMID: 16273340 DOI: 10.1007/s00115-005-2006-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Aphasia is one of the most frequent and disabling consequences of stroke. Poor spontaneous recovery and the limited success of conventional speech therapy bring up the question of how current treatment approaches can be improved. Besides increasing training frequency-with daily sessions lasting several hours and high repetition rates of language materials ("massed training")-adjuvant drug therapy may help to increase therapy efficacy. In this article, we illuminate the potential of monoaminergic (bromocriptine, levodopa, d-amphetamine) and cholinergic (donepezil) substances for treating aphasia. For a final evaluation of combined massed training and adjuvant pharmacotherapy, randomized, placebo-controlled (multicenter) clinical trials with sufficient numbers of patients are needed. Furthermore, results of experimental animal studies of functional recovery in brain damage raise hopes that neurotrophic factors or stem cells might find a place in recovery from aphasia in the intermediate future.
Collapse
Affiliation(s)
- C Korsukewitz
- Klinik und Poliklinik für Neurologie, Universität Münster.
| | | | | | | |
Collapse
|
161
|
Abstract
Multiple sclerosis (MS) is associated with a variety of symptoms and functional deficits that result in a range of progressive impairments and handicap. Symptoms that contribute to loss of independence and restrictions in social activities lead to continuing decline in quality of life. Our aim is to give an updated overview on the management of symptoms and rehabilitation measures in MS. Appropriate use of these treatment options might help to reduce long-term consequences of MS in daily life. First, we review treatment of the main symptoms of MS: fatigue, bladder and bowel disturbances, sexual dysfunction, cognitive and affective disorders, and spasticity. Even though these symptomatic therapies have benefits, their use is limited by possible side-effects. Moreover, many common disabling symptoms, such as weakness, are not amenable to drug treatment. However, neurorehabilitation has been shown to ease the burden of these symptoms by improving self-performance and independence. Second, we discuss comprehensive multidisciplinary rehabilitation and specific treatment options. Even though rehabilitation has no direct influence on disease progression, studies to date have shown that this type of intervention improves personal activities and ability to participate in social activities, thereby improving quality of life. Treatment should be adapted depending on: the individual patient's needs, demands of their surrounding environment, type and degree of disability, and treatment goals. Improvement commonly persists for several months beyond the treatment period, mostly as a result of reconditioning and adaptation and appropriate use of medical and social support at home. These findings suggest that quality of life is determined by disability and handicap more than by functional deficits and disease progression.
Collapse
Affiliation(s)
- Jürg Kesselring
- Department of Neurology and Neurorehabilitation, Rehabilitation Centre, CH-7317, Valens, Switzerland.
| | | |
Collapse
|
162
|
Benedict RHB. Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. J Int Neuropsychol Soc 2005; 11:727-36. [PMID: 16248908 DOI: 10.1017/s1355617705050782] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2005] [Revised: 05/31/2005] [Accepted: 06/07/2005] [Indexed: 11/07/2022]
Abstract
Repeated neuropsychological testing gives rise to practice effects in that patients become familiar with test material as well as test-taking procedures. Using alternate forms prevents the learning of specific test stimuli, potentially mitigating practice effects. However, changing forms could diminish test-retest reliability coefficients. Our objective was to examine test-retest effects in multiple sclerosis (MS) patients randomly assigned to same- (SF) or alternate-form (AF) conditions. Thirty-four MS patients underwent neuropsychological evaluation. The battery included the California Verbal Learning Test II (CVLT-II) and the Brief Visuospatial Memory Test-Revised (BVMT-R), memory tests recommended by a recently convened consensus panel. Patients were randomly assigned to SF or AF groups and then tested at baseline and follow-up examination 1 week later. Analysis of variance tests (ANOVAs) revealed significant group x time interactions, with SF patients showing greater gain than AF patients. SF practice effects were often large, compromising test validity. Reliability coefficients were either equivalent or higher in the AF group, a finding attributed to ceiling effects and reduced variance in the SF group at retest. The generalizability of the findings may be limited to short test-retest intervals and the MS population. Nevertheless, I conclude that the use of CVLT-II and BVMT-R alternate forms likely helps preserve test validity without compromising test-retest reliability.
Collapse
Affiliation(s)
- Ralph H B Benedict
- State University of New York at Buffalo School of Medicine, Department of Neurology, Buffalo General Hospital, New York 14203, USA.
| |
Collapse
|
163
|
Abstract
Donepezil is a selective acetylcholinesterase inhibitor that is widely prescribed for Alzheimer's disease (AD). It has been shown to be of benefit in mild, moderate and severe stages of AD, vascular dementia and dementia associated with Parkinson's disease. Donepezil is absorbed slowly, but completely, from the gut, reaching peak plasma levels in 3-4 h and, with daily dosing, steady-state concentration in 15-21 days. Within a relatively narrow range, there is a linear relationship between dose and pharmacodynamic effects, measured as red blood cell acetylcholinesterase inhibition and clinical efficacy. Donepezil is principally excreted unchanged in the urine, but there is also hepatic metabolism; some of its metabolites may be active. Despite being 96% bound to plasma proteins, it has few interactions with other drugs, and the 5-mg dose can be given safely to patients with mild-to-moderate hepatic and renal -disease. Side effects, which are mainly a consequence of its cholinomimetic mechanism of action, are usually mild and transient. Although donepezil was originally developed to inhibit the breakdown of the neurotransmitter acetylcholine as symptomatic therapy for AD, recent studies raise the possibility of other effects this drug has on the pathogenesis of AD.
Collapse
Affiliation(s)
- Ben Seltzer
- Tulane University School of Medicine, Department of Psychiatry and Neurology, 1430 Tulane Avenue (HC82), New Orleans, Louisiana 70112, USA.
| |
Collapse
|
164
|
Christodoulou C, Melville P, Scherl WF, Morgan T, MacAllister WS, Canfora DM, Berry SA, Krupp LB. Perceived cognitive dysfunction and observed neuropsychological performance: longitudinal relation in persons with multiple sclerosis. J Int Neuropsychol Soc 2005; 11:614-9. [PMID: 16212689 DOI: 10.1017/s1355617705050733] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2004] [Revised: 05/12/2005] [Accepted: 05/20/2005] [Indexed: 11/06/2022]
Abstract
The relation between self-reported cognitive dysfunction and neuropsychological performance over 24 weeks was assessed in a sample of 53 multiple sclerosis patients. Subjects were assessed at Weeks Zero and 24 as part of a clinical trial to enhance cognition. At baseline, subjects had at least mild cognitive impairment on the Rey Auditory Verbal Learning Test and an absence of depression. Neuropsychological performance was assessed with a modification of the well standardized Brief Repeatable Battery. The 5-item Perceived Deficits Questionnaire and a 2-item memory and attention/concentration questionnaire assessed self-perceived cognitive impairment. Self-assessed cognition did not correlate with neuropsychological performance at either baseline or 24 weeks. However, changes in the self-assessment measures did correlate with changes in neuropsychological performance. Patients accurately perceived some changes in their level of cognitive dysfunction, though they were insensitive to the degree of their current dysfunction. Possible explanations of this pattern of results are discussed.
Collapse
Affiliation(s)
- Christopher Christodoulou
- Department of Neurology, State University of New York at Stony Brook, Stony Brook, New York 11794-8121, USA.
| | | | | | | | | | | | | | | |
Collapse
|
165
|
Abstract
PURPOSE OF REVIEW This review of recent work in the area of neurorehabilitation of multiple sclerosis patients surveys progress and underscores the need for further work to evaluate the effectiveness of treatments. RECENT FINDINGS Several recent review documents have summarized the current position regarding neurorehabilitation and symptomatic management in multiple sclerosis. They have highlighted the paucity of evidence underpinning current practice, thereby identifying the need for more scientifically sound studies in both neurorehabilitation and symptomatic treatment. However, as will be apparent from this review, there has been a welcome increase in studies evaluating both aspects of neurorehabilitation and specific areas such as the role of cannabinoids in spasticity and pain and new treatments for cognitive impairment. SUMMARY Overall, there is an encouraging trend both in questioning our current practice and in designing more scientifically sound trials incorporating new and more appropriate outcome measures. There is, however, much more to be done before we are in a position to provide the expert, comprehensive, joined-up, care that is required to meet the complex, ever-changing needs of patients with multiple sclerosis.
Collapse
Affiliation(s)
- Alan J Thompson
- Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery, University College London Hospital, London, UK.
| |
Collapse
|
166
|
Abstract
Donepezil is an acetylcholinesterase inhibitor used to treat Alzheimer's disease. It has been shown to be effective in the treatment of cognitive symptoms, functional impairment and behavioral problems at mild, moderate and severe stages of the disease. Donepezil treatment results in modest short-term (6- to 9-month) improvement in some measures and attenuates the downward course of the disease for 1–3 years. Donepezil reaches peak plasma levels 3–4 h after ingestion and, with daily dosing, steady-state concentration in 14–21 days. The elimination half-life is approximately 70 h, and it is principally excreted unchanged in the urine. There is a linear relationship between plasma level and both red blood cell acetylcholinesterase inhibition and certain cognitive outcome measures. Donepezil is generally safe and well tolerated and, because of its dosing schedule, convenient to prescribe. Ongoing studies are examining the use of donepezil in combination with other drugs for Alzheimer's disease and for other conditions involving cognitive dysfunction.
Collapse
Affiliation(s)
- Ben Seltzer
- Tulane University School of Medicine, Department of Psychiatry and Neurology, 1430 Tulane Avenue (HC82), New Orleans, LA 70112, USA
| |
Collapse
|
167
|
Engel C, Greim B, Zettl UK. Kognitive Defizite bei Multipler Sklerose. DER NERVENARZT 2005; 76:943-4, 946-8, 951-3. [PMID: 15765229 DOI: 10.1007/s00115-005-1901-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Cognitive dysfunctions are frequent symptoms of multiple sclerosis (MS) and occur in up to 65% of patients. Especially memory, attention, executive and visual constructive functions are impaired. These problems strongly affect patients' ability to work, social relationships, and quality of life. Symptoms of physical disabilities can arise independently. Cognitive dysfunctions are clear indicators of MS progression, since they represent highly complex functions depending on the integrity of neuronal networks. Once manifested after a relapse, they remain stable. Given a differentiating diagnosis, it is possible to treat these dysfunctions by cognitive training and pharmacologically for example by immunomodulating drugs. However, treatment options are limited at present. This report provides a detailed description of cognitive functions and performance in MS patients, their comorbidities such as fatigue and depression, currently available diagnostic tools, and therapeutic options.
Collapse
Affiliation(s)
- C Engel
- Klinik und Poliklinik für Neurologie der Universität Rostock.
| | | | | |
Collapse
|
168
|
Abstract
PURPOSE OF REVIEW The aim of the present report is to briefly review multiple sclerosis therapeutic trials published or presented in 2004 to provide an up-to-date overview of the established evidence and new insights. RECENT FINDINGS New data have come available that help us understand how currently approved disease modifying drugs can best be used. Nonetheless, their limited effectiveness - especially in progressive forms of multiple sclerosis - as well as the inconvenience and toxicity associated with their use, emphasize the need for new treatment strategies. A substantial number of reports on new emerging treatment modalities were published in 2004, and one of these modalities was newly approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis. SUMMARY Further advances have been made in the treatment of multiple sclerosis patients. On the one hand, we know better how and in whom to use existing medications. On the other hand, it is exciting to witness how increased insight in the pathophysiology of the disease and its symptoms has led to a series of new, innovative treatment modalities.
Collapse
Affiliation(s)
- Joep Killestein
- Department of Neurology, MS Centre, VU Medical Centre Amsterdam, Amsterdam, The Netherlands
| | | |
Collapse
|
169
|
Chamelian L, Bocti C, Gao FQ, Black SE, Feinstein A. Detecting cognitive dysfunction in multiple sclerosis with a magnetic resonance imaging rating scale: a pilot study. CNS Spectr 2005; 10:394-401. [PMID: 15858457 DOI: 10.1017/s1092852900022768] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE In multiple sclerosis (MS), magnetic resonance imaging (MRI) predictors of cognitive impairment are based on sophisticated computer-generated analyses that are difficult to apply in clinical settings. This study investigated the clinical usefulness of a new visual rating scale, the Cholinergic Pathways Hyperintensities Scale (CHIPS), in detecting cognitive dysfunction. METHODS Forty clinically definite MS patients underwent a brain MRI. Based on the CHIPS, cholinergic pathway hyperintensities were rated in 10 regions on four axial slices. Computerized hyperintense lesion volumes were also obtained. For cognitive testing, The Neuropsychological Screening Battery for Multiple Sclerosis was used. "Low" and "High" lesion score groups were computed based on the mean of the total CHIPS score. Optimal sensitivity and specificity of the total CHIPS score in detecting cognitive impairment were determined using a receiver operator characteristic curve. RESULTS Despite a similar demographic profile, subjects with a "High" lesion score performed significantly worse than the "Low" lesion score group on verbal (P = .007) and visuospatial (P = .02) memory, and on a global index of cognitive functioning (P = .001). Optimal sensitivity (82%) and specificity (83%) were reached with a threshold total CHIPS score of 18 points. Total CHIPS score and total hyperintense lesion load were correlated (sigma = 0.82, P < .0001). CONCLUSION CHIPS is helpful in clinically predicting cognitive impairment in MS.
Collapse
Affiliation(s)
- Laury Chamelian
- Department of Psychiatry, University of Toronto, Toronto, Canada
| | | | | | | | | |
Collapse
|
170
|
Pepping M, Ehde DM. Neuropsychological Evaluation and Treatment of Multiple Sclerosis: The Importance of a Neuro-rehabilitation Focus. Phys Med Rehabil Clin N Am 2005; 16:411-36, viii. [PMID: 15893679 DOI: 10.1016/j.pmr.2005.01.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
This article describes the components of a neuropsychologic evaluation and some of the primary indications for its use in multiple sclerosis (MS). We also detail the kinds of neurocognitive and neurobehavioral problems that are cited commonly in the relevant literature and seen in the clinical setting. We provide a brief overview of the brain structures that are affected commonly by MS, and their implications for neuropsychologic function. We have included an overview of some of the current medications that are used to target cognitive and emotional symptoms that can be a direct result of the disease. We also present four representative case examples of composite patients, and briefly review the ways in which neuropsychologic evaluation and neuro-rehabilitation treatments can help people who have MS.
Collapse
Affiliation(s)
- Mary Pepping
- Department of Rehabilitation Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356490, Seattle, WA 98195, USA.
| | | |
Collapse
|
171
|
D'Intino G, Paradisi M, Fernandez M, Giuliani A, Aloe L, Giardino L, Calzà L. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci U S A 2005; 102:3070-5. [PMID: 15710875 PMCID: PMC548798 DOI: 10.1073/pnas.0500073102] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Clinical symptoms in multiple sclerosis include cognitive dysfunction. Difficulties in learning and remembering new information represent the most common cognitive deficit and are associated with a general and progressive brain pathology. Possible pathogenetic mechanisms for neuronal damage such as neuroprotective strategies are under active investigation also in experimental allergic encephalomyelitis, the most widely used experimental model for multiple sclerosis. In this paper we demonstrate that a selective deficit in learning and memory performance, as investigated by the Morris water maze test, is a consistent feature in rat encephalomyelitis, which correlates with a decline in choline acetyltransferase activity and nerve growth factor mRNA level in cerebral cortex, hippocampus, and basal forebrain. Treatment aimed to restore acetylcholine content through chronic administration of selective acetylcholinesterase inhibitors (rivastigmine and donepezil) restores cognitive performance, choline acetyltransferase activity, and nerve growth factor mRNA expression.
Collapse
Affiliation(s)
- Giulia D'Intino
- Department of Veterinary Morphophysiology and Animal Production, University of Bologna, 40064 Ozzano Emilia (Bologna), Italy
| | | | | | | | | | | | | |
Collapse
|
172
|
|